Consensus Vertex Pharmaceuticals Incorporated Sao Paulo

Stocks

VRTX34

BRVRTXBDR001

Pharmaceuticals

Market Closed - Sao Paulo 07:05:00 07/10/26 am AEDT			5-day change	1st Jan Change
80.00 ^BRL	+1.52%		-6.83%	+2.25%

28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT

8fd1aab0ff04e5f67d741660db35a.3NVtj_cC6-dUpAJxMLOhQXH0ExQImSs-Vh0SEcU8NUk.uKYfybNLjqwTyUdEeN7FIDm6YiBhqxtKAUh_KKEPVz6E5Srex3vfiBv1aQ~528c613e56dc88b8bf233fc3f3d5667b

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
03/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
13/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
11/08	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
11/08	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
06/08	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
05/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
05/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
04/08	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
04/08	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
04/08	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
04/08	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
04/08	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
04/08	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
04/08	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
21/07	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
20/07	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
14/07	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
10/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
08/07	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
08/07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating	MT
07/07	Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+14.8%
	JOHNSON & JOHNSON					+9.76%
	ABBVIE INC.					+5.1%
	MERCK & CO., INC.					+10.16%
	ROCHE HOLDING AG					+7.39%
	NOVARTIS AG					+7.01%
	ASTRAZENECA PLC					+32.09%
	AMGEN INC.					-2.92%
	GILEAD SCIENCES, INC.					+10%
	Average					+10.38%
	Weighted average by Cap.					+10.94%